Recent discoveries in the non-coding genome have challenged the original central dogma of molecular biology, as non-coding RNAs and related processes have been found to be important in regulating gene expression. MicroRNAs and long non-coding RNAs (lncRNAs) are among those that have gained attention recently in human diseases, including cancer, with the involvement of many more non-coding RNAs (ncRNAs) waiting to be discovered. ncRNAs are a group of ribonucleic acids transcribed from regions of the human genome, which do not become translated into proteins, despite having essential roles in cellular physiology. Deregulation of ncRNA expression and function has been observed in cancer pathogenesis. Recently, the roles of a group of ncRNA known as lncRNA have gained attention in cancer, with increasing reports of their oncogenic involvement. Female reproductive cancers remain a leading cause of death in the female population, accounting for almost a third of all female cancer deaths in 2016. The Wnt signalling pathway is one of the most important oncogenic signalling pathways which is hyperactivated in cancers, including female reproductive cancers. The extension of ncRNA research into their mechanistic roles in human cancers has also led to novel reported roles of ncRNAs in the Wnt pathway and Wnt-mediated oncogenesis. This review aims to provide a critical summary of the respective roles and cellular functions of Wnt-associated lncRNAs in female reproductive cancers and explores the potential of circulating cell-free lncRNAs as diagnostic markers and lncRNAs as therapeutic targets. LGR5, leucine-rich repeat-containing G-protein coupled receptor 5; lncRNA, long non-coding RNA; LRP, lipoprotein receptor-related protein; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; miRNA, microRNA; NBAT1, neuroblastoma-associated transcript 1; ncRNA, non-coding RNAs; NEAT1, nuclear-enriched abundant transcript 1; NGS, next-generation sequencing; PCA3, prostate cancer antigen 3; PCDH10, protocadherin 10; PCP, Wnt/planar cell polarity; PCR2, polycomb repressive 2; Pinc, pregnancy-induced non-coding RNA; RNAi, RNA interference; shRNA, short hairpin RNAs; TCF, transcription factors T cell factor; UCA1, urothelial carcinoma-associated 1
Introduction -the role of lncRNAs and cancer
With the discovery of the nucleic acid structure by Watson and Crick in the 1950s, the 'central dogma of molecular biology' was born as a description of how genetic information was transferred in the cell. For decades, RNA has been widely accepted to function as the bridging molecule between the DNA and the expression of functional proteins, during transcription of DNA into mRNA and the translation of mRNA into proteins. Until recently, most of the focus of RNA research has been on protein coding mRNA, which accounts for about 2% of the human genome (International Human Genome Sequencing Consortium, 2004; Frith et al., 2005) . The remaining 98% of the human genome, according to the original central dogma of molecular biology, has been considered as 'junk', which was thought to be largely un-transcribed and to have no functions in gene regulation. In contrast to the transcribed mRNA, non-coding RNA (ncRNA) are transcribed but are not translated into proteins. A revolution in ncRNA research occurred in 1993, with the discovery of the first small ncRNA known as microRNA (miRNAs), as a type of regulatory ncRNA (Fire et al., 1998; Almeida et al., 2011) . Novel groups of ncRNAs were also later discovered (Table 1) (Esteller, 2011) , with different methodologies, such as chromatin-state maps and RNA-seq (Guttman et al., 2009; Khalil et al., 2009; Orom et al., 2010; Rinn et al., 2007) . Although only 2% of the human genome encodes for proteins, 75% of the genome now is known to produce primary transcripts, and of those, 62% are processed transcripts, making ncRNAs, including ribosomal RNAs and other housekeeping RNAs, the majority of primary transcripts .
Recently, the transcript data from many databases and FANTOM 5 0 cap analysis of gene expression cluster analysis identified 27 919 human long non-coding RNAs (lncRNAs), with expression profiles in both primary cells and tissue samples. Furthermore, 69% of these lncRNAs were suggested to be potentially functional (Hon et al., 2017) . These lncRNAs are a diverse group of RNAs, arbitrarily defined as an RNA that is 200 nucleotides or more in length without protein coding functions (Cech and Steitz, 2014; Derrien et al., 2012) . Although nucleotide lengths arbitrarily classify lncRNAs, they are functionally distinct. lncRNAs consist of distinctly unique RNA transcripts, classified based on their genomic location. They include sense lncRNAs, bidirectional lncRNAs, intronic lncRNAs, intergenic lncRNAs, small nucleolar RNA and intergenic RNAs, with most lncRNAs residing primarily in the nucleus for their functions (Table 1) (Batista and Chang, 2013; Fatima et al., 2015) . lncRNAs have been shown to possess many different functions such as regulating gene expression and modulating various signalling pathways. lncRNAs can regulate gene expression by distinct molecular mechanisms, broadly classified into epigenetic, transcriptional and posttranscriptional Fatima et al., 2015) . Regulatory lncRNAs have different structural domains embedded in the sequence, which determine the functions of the lncRNAs. These domains can be RNA-, protein-and possibly DNA-binding domains. The presence of RNAbinding domains that allow imperfect complementary binding and of protein-binding domains that interact with many different proteins in differing combinations, results in a variety of lncRNA species with differing modular structure and functions (Mercer and Mattick, 2013) . Moreover, such diverse functions of lncRNAs have also been suggested to be influenced by the different subcellular localizations, which can be either distinctly localized in the nucleus or cytoplasmic region, despite some having nonspecific localization within the cell. In the cytoplasm, lncRNA generally functions in a post-transcriptional manner, affecting the state of mRNA, whereas in the nucleus, lncRNA regulates both epigenetically by interacting with chromatin-remodelling complexes and also transcriptionally by binding to either general transcription machineries or specific regulatory factors (Zhang et al., 2014a; Chen, 2016b) . lncRNAs can interact with complexes such as switching defective/sucrose non-fermenting at different subunits to activate or inhibit gene expression, epigenetically (Cao et al., 2002; Mattick, 2009; Margueron and Reinberg, 2011; Davidovich et al., 2013; Tang et al., 2017) . lncRNAs are also able to interact with chromatin modifying complexes such as polycomb repressive complexes to regulate gene expression epigenetically (Cao et al., 2002; Mattick, 2009; Margueron and Reinberg, 2011) . In some cases, lncRNAs exert epigenetic control by acting as a scaffold during chromatin modification and even have higherorder chromosomal interactions to regulate chromosome structure (Batista and Chang, 2013) . Furthermore, the function of lncRNAs can also be classified as either cis-acting or trans-acting, which involves the regulation in the vicinity of the transcription sites or regulation independent of loci of transcription respectively (Chen, 2016b -7, miR-21, miR-34, miR-122, miR-142,miR-150, miR-155, let-7 family, miR-374a, miR-183, miR-200 clusters (Pasquinelli, 2012) Piwi-interacting RNA Single-stranded RNA of approximately 27 nucleotides interacting with PIWI proteins and functions in the repression of mobile elements (e.g. transposons). Additional role in targeting mRNA de-adenylation has been reported. (Weick and Miska, 2014) Small nuclear RNA (snRNA)
Small RNA species that function in the nucleus and are involved in RNA processing and splicing.
U1, U2, U4, U5, U6, U7, U11, U12 snRNA (Matera et al., 2007; Valadkhan and Gunawardane, 2013) Small nucleolar RNA (snoRNAs)
Short RNA of about 60-600 nucleotides with two major families: C/D and H/ACA. snoRNAs associate with specific proteins to form ribonucleoproteins (snoRNPs) and function in pre-ribosomal RNA modification and processing. C/D snoRNAs, H/ACA snoRNAs (Dragon et al., 2006; Matera et al., 2007) With the advancement of technology such the use of RNA-sequencing, the ability to detect and quantify RNA species has increased, and this has resulted in the identification of the different subclasses of ncRNAs. These ncRNAs not only possess distinct characteristics but also varying functions in cellular biology.
Recently,the deregulation of lncRNAs in cancer has gained attention, as shown by the increasing number of reports of their oncogenic involvement (Huarte, 2015) . lncRNAs have been found to play roles in cancer pathogenesis via various mechanisms, including aberrant lncRNA expression, single nucleotide polymorphisms of functional lncRNAs, cis/trans regulation of cancer associated genes by lncRNAs and changes to post-transcriptional regulation of lncRNAs (Huarte, 2015) . The involvement of lncRNAs and cancer was first reported in prostate cancer, where two lncRNAs -prostate cancer antigen 3 (PCA3) and prostatespecific transcript 1 -were found to be aberrantly expressed (Bussemakers et al., 1999; Srikantan et al., 2000) . Following this report of the involvement of lncRNAs in prostate cancer, other lncRNAs were also discovered to be involved in several other cancers. One example is the lncRNA metastasisassociated lung adenocarcinoma transcript 1 (MALAT1), a nuclear lncRNA that was first found overexpressed in lung cancer and, later, in other cancers including breast, colon and hepatocellular carcinoma (Ji et al., 2003; Huarte, 2015) . In another example, the HOX transcript antisense RNA (HOTAIR) lncRNA has been found to be involved in cancer pathology, where overexpression of HOTAIR has been associated with cancer progression in breast cancer metastasis and also in 26 different tumour types (Gupta et al., 2010; Bhan and Mandal, 2015; Hajjari and Salavaty, 2015) .
Moreover, in a genome-wide association study, the majority of genetic polymorphisms associated with cancer were found in the non-coding regions of the genome. This suggests that the lncRNAs could also be affected by these polymorphisms when transcribed from the regions of high cancer risk genome (Cheetham et al., 2013) . In more recent studies, inherited single nucleotide polymorphism (SNP) in the homeobox protein Hox-A11 (HOXA11)-AS (A > T), HOXA11-AS rs17427875 minor allele, can result in inhibition of proliferation, migration and invasion of epithelial ovarian cancer cells, inhibiting oncogenesis (Richards et al., 2015) . Variant SNPs in lncRNA MIR2052HG can also alter the risk of recurrence of breast cancer in patients treated with aromatase inhibitors (Ingle et al., 2016) . Such preliminary evidence suggests that genetic polymorphism can significantly influence the risk and development of cancer.
Introduction -female reproductive cancers
Female reproductive cancers remain a leading cause of death in the female population, with breast cancer being the most common cancer diagnosed globally, and amongst the most frequent causes of cancer death worldwide (Ferlay et al., 2015) . In treating cancer, in addition to surgical management, chemotherapy and radiotherapy, targeted therapies directed at specific molecules in cancer progression are also utilized. Targeted therapies involve the use of drugs against cells harbouring specific molecular aberrations to inhibit cancer growth, by blocking growth factors-dependent pathway such as EGFR, HER2 (trastuzumab emtansine in breast cancer) and VEGF (bevacizumab in breast, ovarian and cervical cancers) or inducing apoptotic pathways (PI3K inhibitors -BKM120 in breast cancer trials). Some of these drugs that target essential cancer pathways may also be used in more than one type of cancer. PARP inhibitors such as Racuparib and Niraparib that target ovarian cancer exhibiting BRCA1/2 mutations have also been approved as a type of target therapy, disrupting effective DNA repair pathway and resulting in cell death by synthetic lethality (Munagala et al., 2011; Boyraz et al., 2013; Lokadasan et al., 2016) . In addition, other potential therapeutic agents also include COX-2 inhibitors (celecoxib in ovarian cancer trials) and histone deacetylase inhibitors (entinostat in breast cancer) (Zagouri et al., 2012; Connolly et al., 2017) . On the other hand, for endometrial cancers, hormonal therapy such as progestin-containing regimens or anti-oestrogen regimens, is carried out when required (Carlson et al., 2014) .
The Wnt signalling pathway and associated female reproductive cancers Like other cancers, female reproductive cancers are a result of deregulated signalling pathways. One of the signalling pathways more often aberrantly activated during female reproductive oncogenesis, is the Wnt signalling pathway.
The Wnt signalling pathway, which is further divided into β-catenin-dependent (Wnt/β-catenin) and β-cateninindependent signalling pathways, is a highly evolutionally conserved pathway essential in numerous cellular processes during growth, development and adult homeostasis (Komiya and Habas, 2008; MacDonald et al., 2009; Niehrs, 2012) . The Wnt/β-catenin signalling pathway is the best characterized Wnt pathway that predominantly involves β-catenin, an important transcriptional co-activator that translocates into the nucleus to bind DNA-bound transcription factors, such as T cell factor (TCF)/lymphoid enhancer factor family of proteins, during Wnt activation. This activation is triggered by the binding of Wnt proteins to Frizzled receptors and lipoprotein receptor-related protein (LRP) 5/6 and leads to the transcription of Wnt target genes, which are predominantly genes required for oncogenic transformation, such as cyclin D1 (CCND1) and c-MYC (Niehrs, 2012) .
The β-catenin-independent pathway has been classified further into two main pathways, the Wnt/planar cell polarity (PCP) and the Wnt/Ca 2+ pathways, and the latter consists of a number distinct pathways and modulators whose exact mechanisms remain poorly understood (Niehrs, 2012) . The Wnt/PCP pathway is the best-characterized pathway of the β-catenin-independent pathways. During Wnt/PCP signalling activation, non-canonical Wnts (e.g. Wnt-5a) bind Frizzled receptors to activate a cascade of signalling mechanisms involving small Rho GTPases such as Rac1, Rho and JNK (Veeman et al., 2003; Ginger et al., 2006; Niehrs, 2012) . This leads to changes in the cytoskeleton remodelling and cell polarity, as well as activation of JNK-dependent transcriptional activity and transcription of JNK target genes. Alterations in the Wnt signalling pathway components lead to physiological and cellular changes associated with female reproductive cancers (Gatcliffe et al., 2008b; Geyer et al., 2011; Dellinger et al., 2012; Arend et al., 2013; Zhang et al., 2014b; Muñoz Bello et al., 2015) . For example, in breast cancer, overexpression of Wnt pathway components, such as Wnt receptors LRP6 and Frizzled 7, and silencing of Wnt inhibitors such as secreted frizzled-related proteins have been reported (Veeck et al., 2006; Liu et al., 2010; Arend et al., 2013) . The overexpression of leucine-rich repeatcontaining G-protein coupled receptor 5 (LGR5) in breast cancer was shown to regulate tumourigenicity, epithelial-mesenchymal transition (EMT) (Bergenblock et al., 2012) and breast cancer stem cells through canonical Wnt/β-catenin signalling (Yang et al., 2015a,b,c) . Suppression of the Wnt/β-catenin pathway in breast cancer inhibits cancer metastasis (Jang et al., 2015) .
In ovarian cancer, overexpression of Frizzled 7 has been reported, through the β-catenin-independent Wnt/PCP pathway (Asad et al., 2014) . In high-grade serous ovarian carcinoma, Wnt/β-catenin signalling is up-regulated and also confers platinum resistance (Nagaraj et al., 2015) . Wnt/β-catenin signalling is more active in A2780cp ovarian cancer cells (cisplatin-resistant) compared to A2780s cells (cisplatin-sensitive) and inhibition of β-catenin signalling sensitizes A2780cp cells towards carboplatin toxicity (Barghout et al., 2015) .
The involvement of Wnt signalling is also evident in endometrial cancers, with the β-catenin gene showing activating mutations in exon 3 and also aberrant nuclear localization (Fukuchi et al., 1998; Moreno-Bueno et al., 2002) . It appears Consistent with these findings, aberrant nuclear β-catenin is predominantly expressed in ovarian endometrioid adenocarcinomas (Gatcliffe et al., 2008a) . Moreover, high-mobility group AT-hook 1 (HMGA1) protein is overexpressed in endometrial cancers and regulates cell migration and invasion by activating the Wnt/β-catenin pathway (Han et al., 2016) . In endometrial cancers, the Wnt10b protein drives cellular proliferation and inhibition of apoptosis through the Wnt/β-catenin pathway (Chen et al., 2013b) .
In cervical cancer, the Wnt/β-catenin pathway drives cellular invasion and proliferation, which is regulated by LGR5 and the enhancer of zeste homologue 2 (EZH2) (Chen et al., 2014; Chen et al., 2016) . Prolyl isomerase (Pin1) expression in cervical cancer also contributes to chemo-resistance by regulating Forkhead Box M1 (FOXM1) and Wnt/β-catenin signalling (Wang et al., 2016b) . lncRNAs in Wnt-mediated pathogenesis in female reproductive cancers lncRNAs, with roles in cellular physiology and cancer, are associated with Wnt-mediated oncogenic mechanisms (Jiang et al., 2016a) . Some lncRNAs were even reported as direct Wnt target genes, such as MYU and CCAL in colorectal cancer cells (Arun et al., 2016; Kawasaki et al., 2016; Mir et al., 2016; Sunamura et al., 2016) , Mrhl RNA in mouse spermatogonial cells (Akhade et al., 2016) , urothelial carcinoma-associated 1 (UCA1) in bladder cancer (Fan et al., 2014) , HOTAIR in pancreatic ductal adenocarcinoma (Jiang et al., 2016a,b) , FOXD2-AS1 and nuclear-enriched abundant transcript 1 (NEAT1) in non-small cell lung cancer (Rong et al., 2017; Sun et al., 2017) . Evidence of lncRNAs being involved in the Wnt signalling cascade has been obtained in female reproductive cancers. Below, we review the roles and mechanisms of Wnt-mediated lncRNAs in female reproductive cancers.
Breast cancer
The expression of several lncRNAs, such as NEAT1 and pregnancy-induced non-coding RNA (Pinc1), is involved in development and function of the mammary gland (Ginger et al., 2006; Sandhu et al., 2016) . The lncRNA NEAT1 was essential in sustaining lobular-alveolar development and ductal branching of the breast anatomy, affecting mammary gland and lactation capability. On the other hand, Pinc1, whose expression is regulated during developmental stages, was required in the regulation of epithelial cell differentiation and regulating cell fate, in association with polycomb repressive 2 (PCR2) (Ginger et al., 2006; Piao and Ma, 2012) . In addition to normal physiological function, lncRNAs are also deregulated in breast cancer development and progression. Some examples include growth arrest-specific 5 (GAS5), BC200, HOTAIR and H19 (Piao and Ma, 2012; Shore et al., 2012) . In breast cancer, expression of lncRNAs such as BC200 and HOTAIR is up-regulated. In particular, increased BC200 was associated with invasive breast cancer with poorer prognosis, whereas HOTAIR was more recently identified to be up-regulated in tamoxifen-resistant, oestrogen receptor (ER)-positive breast cancer (Iacoangeli et al., 2004; Gupta et al., 2010; Xue et al., 2015) . H19 expression was observed to be elevated in breast cancers, particularly in ER-positive tumours, which has been reported to induce breast cancer cell growth Zhang et al., 2016a) . The deregulation of GAS5, which was downregulated in breast cancer, up till stages II and III, can influence the sensitivity of breast cancer cells to apoptosis (Mourtada-Maarabouni et al., 2009) . Such evidence demonstrate the involvement of lncRNAs in both normal and diseased breast functions, although the mechanism(s) underlying how these lncRNAs led to the development and progression of breast cancer is still to be established.
In particular, lncRNAs have been shown to modulate Wnt/β-catenin signalling through altering the expression and activity of essential Wnt/β-catenin modulators. UCA1, a lncRNA that can exist in two different isoforms, affected the expression of negative regulators of the Wnt/β-catenin pathway, such as glycogen synthase kinase 3β (GSK3β), whereby the knockdown of UCA1 resulted in an increase in both GSK3β and phospho-Ser 9 -GSK3β (inactive p-GSK)
protein levels. The increase in GSK3β, which is essential in the inhibition of both phosphorylation and subsequent degradation of β-catenin directed by TrCP, suggests a decrease in Wnt signalling ( Figure 1A ) (Xiao et al., 2016) . Moreover, altering UCA1 expression can also affect β-catenin expression, as UCA1 knockdown suppressed β-catenin expression and a subsequent reduction in downstream target genes (CCND1 and MMP-7), indicating a decrease in Wnt/β-catenin activity. The up-regulation of UCA1 was deduced to activate the Wnt/β-catenin signalling pathway and promote EMT and invasion in breast cancer (Xiao et al., 2016) . Furthermore, UCA1 affect Wnt/β-catenin signalling, as knockdown of UCA1 resulted in the inhibition of nuclear translocation of β-catenin and subsequent Wnt/β-catenin signalling ( Figure 1A ). Therefore, UCA1 suppression could contribute to enhanced sensitivity to tamoxifen and reduced tumourigenicity in breast cancer and vice versa . In another example, the suppression of colon cancerassociated transcript 2 (CCAT2), a lncRNA found highly expressed in breast cancer, inhibited Wnt/β-catenin signalling by decreasing the expression levels of β-catenin in both nucleus and cytoplasm, thereby decreasing Wnt/β-catenin activity ( Figure 1B) . Suppression of CCAT2 also resulted in reduction in tumourigenicity, with decreased proliferation and invasion ( Figure 1B ) (Cai et al., 2015) . lncRNA neuroblastoma-associated transcript 1 (NBAT1) was also identified to mediate Wnt/β-catenin signalling through modulating the expression of Dickkopf-related protein 1 (DKK1), a negative regulator of Wnt/β-catenin signalling, by interacting with co-receptor LRP5/6 at the membrane and antagonizing the binding of canonical Wnts, during activation of the Wnt pathway (Niehrs, 2006) . Upregulation of DKK1 expression induced by NBAT1 was mediated by EZH2, which is an essential catalytic subunit of the PCR2 that is also highly expressed in breast cancers ( Figure 1D ). NBAT1 represses EZH2 activity by suppressing the tri-methylation of histone H3-Lys 27 at the DKK1 promoter and hence restoring DKK1 promoter activity ( Figure 1D ). This results in the suppression of metastatic capability of breast cancer cells (Bachmann et al., 2006; Hu et al., 2015) .
Ovarian cancer
lncRNAs have been suggested to contribute to oocyte and early embryonic development (Fitzgerald et al., 2016) , and differential expression profiles of lncRNAs have been observed between cumulus cells of oocytes derived from a high-quality embryo and poor-quality embryo, analysed via microarray . The roles of lncRNAs in the Figure 1 lncRNAs in Wnt/β-catenin signalling. UCA1 down-regulates expression of GSK3β, resulting in the subsequent increase in stabilization and translocation of its substrate β-catenin into the nucleus. Both UCA1 and CCAT2 are able to up-regulate the expression of β-catenin, leading to activation of downstream target genes. MALAT1 expression is induced by canonical Wnt/β-catenin signalling, leading to an increase in cancer cell proliferative potential. NBAT1 modulates the canonical Wnt/β-catenin signalling by inducing the expression of DKK1, a well-known antagonist of the Wnt/β-catenin signalling pathway.
development of ovarian cancer could suggest their importance in ovarian somatic tissue function, which is often the origin of transformed cells in ovarian cancers. Furthermore, ovarian cancer cells of different metastatic capabilities were identified to have a differential expression lncRNA profile, in particularly the metastatic-related lncRNAs (Liu et al., 2013) . Several lncRNAs such as HOXA11 Antisense, NR_026689, C17orf91 and AB073614 have also been identified to be involved in promoting proliferation and invasion in ovarian cancers (Cheng et al., 2015; Li et al., 2016b; Yim et al., 2016; Zhang et al., 2017) . Expression of several lncRNAs was found to be regulated by ER in ER-positive ovarian cancer cells. The clinical significance of these RNAs was shown by the more malignant phenotype of ovarian cancer with aberrant expression of TC0100223, TC0101686 and TC0101441 (Qiu et al., 2014) . lncRNAs such as C17orf91 and AB073614, as mentioned above, were also shown to correlate with poorer prognosis in patients (Cheng et al., 2015; Li et al., 2016b) . Therefore, the roles these lncRNAs play in ovarian carcinomas suggest their potential in contributing to cancer progression and hence they could also serve as potential prognostic markers. Many lncRNAs contribute to the development and progression of ovarian cancers, as mentioned above. These lncRNAs include MALAT1 and UCA1, which also relate to Wnt/β-catenin signalling in endometrial cancers and in breast cancers respectively . Although the mechanisms of some of these lncRNAs in carcinogenesis via transcriptional and translational regulation of gene expression are known, the details of how these lncRNAs interact with Wnt signalling modulators in ovarian cancers will require further investigation (Nikpayam et al., 2017) . In ovarian cancer, lncRNA HOTAIR was identified to correlate positively with β-catenin levels, as overexpression of HOTAIR resulted in increased β-catenin levels, and this also coincided with increased cellular proliferation. Furthermore, chemoresistance was also induced through the activation of the Wnt/β-catenin pathway, while the use of a Wnt/β-catenin inhibitor could partially reverse chemoresistance in HOTAIR overexpressing cells (Li et al., 2016a,b) . However, the exact mechanism of how HOTAIR activates Wnt/β-catenin has not been clearly elucidated.
Uterine/endometrial cancer lncRNAs have been associated with both normal physiological function and with diseased conditions of the endometrium. The transcription factor HOXA10, which is important in fertility through affecting endometrial decidualization and embryo implantation, is also capable of significantly altering mRNA and lncRNA expression involved in the processes of blood vessel development, cell cycle and oocyte meiosis. Thus, lncRNAs are necessary in the normal physiology of women, in preparation for pregnancy (Lin et al., 2015) . Expression profiles of lncRNAs were altered in patients with endometriosis, compared to healthy individuals. Significantly altered lncRNA expression profiles were also observed in endometrial cancers, compared to normal endometrium (Zhai et al., 2015) . The use of lncRNA-mRNA co-expression network and microarray data identified coexpression of several mRNAs (ALCAM, TDRD10 and POLR3E) and lncRNAs (KIAA0087, RP11-501O2, FAM212B-AS1, LOC102723552, RP11-140I24 and RP11-600K151) that are likely to be involved in endometrial cancers, as these RNAs were down-regulated in endometrial cancers, compared to normal endometrium (Xu et al., 2016) . These findings are suggestive of the involvement of lncRNAs in tumour initiation and progression and could serve to provide more information on the development of endometrial cancers.
In endometrial cancers, the Wnt/β-catenin pathway also regulated the expression of lncRNAs. MALAT1 expression was up-regulated with Wnt/β-catenin signalling activation, where increased TCF-4 promoter activity was observed ( Figure 1C ) (Ji et al., 2003) . Promoter hypermethylation and subsequent silencing of protocadherin 10 (PCDH10), a potential cancer suppressor, induced the increase in Wnt/β-catenin signalling. Although the transcriptional silencing of PCDH10 due to hypermethylation has been commonly observed in endometrial cancers, the underlying mechanism of how PCDH10 down-regulation affects Wnt signalling is still unknown. However, the increase in MALAT1 modulated by the increase in Wnt signalling could be responsible for increase in cell proliferation and contribute to endometrial cancer development (Zhao et al., 2014) .
Cervical cancer
In normal cervical physiology, lncRNA such as HOXA11 Antisense is involved as its level varied over the menstrual cycle (Kim et al., 2016) .Expression of lncRNAs in cervical cancers was also shown to differ significantly between carcinomas and normal cervical tissues, even at an early stage of neoplasia (Gibb et al., 2012) . Moreover, high levels of several lncRNAs such as MALAT1, HOTAIR and GAS5 have shown to correlate with poorer prognosis of cervical cancer and are involved in the progression of this cancer in terms of growth and invasion (Yang et al., 2015b) . Similar to ovarian, endometrial and breast cancers, lncRNAs were involved in cervical cancer development and progression in which mechanisms involved in proliferation, apoptosis, invasion and metastasis have been reported . Unsupervised hierarchical clustering of the lncRNAs in female reproductive disease has also revealed distinct populations in breast, ovarian, endometrial and cervical cancers, expressing different levels of these lncRNA. However, involvement of Wnt/β-catenin signalling in the role of lncRNAs in cervical cancer has not been elucidated.
Mutation analysis of two independent patient cohorts, TCGA cohort and Affymetrix U133P2 meta-cohort, observed differential lncRNAs expressions in the female reproductive cancers, breast, cervical and ovarian and endometrial/uterine cancer (Figure 2) . Expression of HOTAIR lncRNA was mostly increased in breast cancer but decreased in ovarian cancer (Figure 2 ). On the contrary, UCA1 expression was increased in ovarian cancer but decreased in breast cancer (Figure 2 ). This further illustrates the importance of specific lncRNAs in the tumourigenesis of female reproductive cancers. Differential expressions of these selected lncRNAs observed in clinical samples further corroborated with in vitro findings, adding importance to the roles played by these lncRNAs in female reproductive cancers. These lncRNAs affect Wnt/β-catenin signalling and subsequently bring about cellular physiological effects, reviewed in earlier sections (Figure 2 and Table 2 ). However, such evidence is limited and, therefore, more needs to be done to identify other participating members and formulate concrete mechanisms of action for their roles in the Wnt/β-catenin signalling pathway.
lncRNAs in Wnt-mediated pathogenesis in other cancers
At present, knowledge of Wnt-associated lncRNAs in female reproductive cancers is limited, few details are known, mechanistically or functionally. However, there is also evidence of lncRNAs in the regulation of Wnt signalling in other cancers that can provide further insights on how lncRNAs can interact with Wnt modulators in the pathway. For instance, AK126698, which is downregulated in non-small cell lung cancer, negatively regulates Frizzled receptor 8 (FZD 8 ) and results in the inhibition of Wnt/β-catenin pathway. This could have a functional effect in promoting cell proliferation and migration with increased Wnt/β-catenin signalling, in the absence of AK126698 . Similarly, the lncRNA papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3), whose expression is decreased in glioma cells, down-regulated LRP6 expression and inhibited Wnt/β-catenin signalling (Xia et al., 2017) . β-catenin was also found to interact with lncRNAs. For example, lncRNA RBM5-Anti-Sense 1(AS1) has been identified in colon cancer-initiating cells to interact with β-catenin selectively to promote β-catenin-TCF4 occupancy at the promoter of Wnt-associated target genes for growth and survival (Di Cecilia et al., 2016) .
In another example, lncRNA mrhl, which is usually down-regulated, can inhibit Wnt/β-catenin by binding to partner protein Ddx5/p68 in a complex. Ddx5/p68, which is required for the nuclear translocation of β-catenin, can dissociate from the complex in the absence of mrhl and lead to the activation of Wnt/β-catenin signalling to promote up-regulation of meiotic differentiation marker genes. However, these lncRNAs can also regulate Wnt/β-catenin signalling, in addition to its role in regulating Wnt/β-catenin signalling as described above. In the case of lncRNA mrhl, activation of Wnt/β-catenin can increase Ctbp1-mediated repression at the promoter region of lncRNA mrhl via histone modification, resulting in the down-regulation of lncRNA mrhl (Arun et al., 2012; Akhade et al., 2015) .
Another lncRNA that is regulated by Wnt/β-catenin signalling would be Wnt-regulated lncRNA, WiNTRLINC1 and a direct TCF4/β-catenin target gene that regulates expression of ASCL2 in colon cells. ASCL2, which is a transcription factor involved in regulating intestinal stem cell fate, can then regulate WiNTRLINC1 transcriptionally in a positive feedback loop to achieve the overall cellular effect (Giakountis et al., 2016) .
In conclusion, as described in other cancers, recent findings have provided more insight on Wnt-associated lncRNA, which also suggest its possibility of its function in female reproductive cancers. However, it is also observed that the relationship between Wnt signalling and lncRNA can be complex and further in-depth investigation is required.
Figure 2
Heatmap of lncRNAs (high expression, red; low expression, green) and unsupervised hierarchical clustering of female reproductive cancers in (A) TCGA cohort and an (B) Affymetrix U133P2 meta-cohort. TCGA Mutation data, and FPKM gene expression of breast cancer (BRCA), cervical and endocervical cancer (Di Cecilia et al.) , ovarian cancer (OV) and uterine corpus endometrial cancer (UCEC) were downloaded from Broad firehose, version 2016_01_28. lncRNA gene expression was extracted from the dataset and subjected to unsupervised hierarchical clustering. Meta-cohort of breast, ovarian and uterine endometrial cancer arrayed on Affymetrix U133 Plus2 previously processed and compiled . The RMA-normalized dataset was combined, quantile normalized and z-score transformed using Matlab R2016b version 9.1.0.441655 (MathWorks; Natick, MA). The dataset was subsequently subjected to unsupervised hierarchical clustering. Color bar indicates the cancer type: breast (BRCA; dark blue), cervical (CESC; light blue), ovarian (OV; yellow) and uterine (UCEC; maroon) carcinoma.
lncRNAs for diagnosis and pharmacological targeting lncRNA diagnostic biomarkers Dozens of lncRNAs are overexpressed in a range of cancers such as breast, ovary, bladder, colorectal, brain and prostate, making them attractive biomarkers and prognostic markers (Wapinski and Chang, 2011; Wahlestedt, 2013; Chen et al., 2013a,b; Fatima et al., 2015; Huarte, 2015) .
Deregulation of lncRNA expression observed in cancers is mirrored in bodily fluids, in cell free serum, plasma and urine (Silva et al., 2015; Qi et al., 2016a) . These circulating cell-free lncRNAs secreted from tumour sites were found to be stably expressed in plasma, and their extremely long half-life makes them suitable biomarkers. Specific lncRNAs are deregulated in cancer, compared to normal tissues, allowing their circulating plasma levels to be used in cancer patients, as a biomarker (Clark et al., 2012; Rapisuwon et al., 2016; Shi et al., 2016) . For instance, PCA3, which was the first lncRNA to be associated with prostate cancer, has potential as a biomarker for early detection of prostate cancers, by taking serum or urine samples. The validity of PCA3 detection in urine has a sensitivity of 57-62% and specificity of 71-72% in two different cohort studies. The levels of this lncRNA can be measured via PROGENSA PCA3, which is a molecular testing kit approved by the Food and Drug Administration (FDA), suggesting its relevance to clinical settings. However. more information about the immediate and long-term value of testing has still to be acquired (Clark et al., 2012; Bradley et al., 2013; Lee et al., 2014; Merola et al., 2015; Qi et al., 2016b) . Because of the increased number of reports and greater knowledge of the mechanisms of lncRNAs in female reproductive cancers, more members of the lncRNA family have been identified as potential biomarkers for diagnosis and for disease monitoring. This use of the lncRNAs depends on their differential expression in normal and diseased states (Zhao et al., 2016) . For example, in breast cancer, circulating lncRNA H19 has been proposed to be a novel circulating biomarker in plasma, with specificity of 87% and sensitivity of 57% (Zhang et al., Promotes epithelial-mesenchymal transition (Bergenblock et al., 2012) and invasion (Xiao et al., 2016) Promotes nuclear translocation of β-catenin to enhance Wnt/β-catenin signalling
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Increases tumourigenicity with increased proliferation and invasion (Cai et al., 2015) •NBAT1 Induces up-regulation of DKK1 by repressing EZH2 activity and hence suppressing the trimethylation of histone H3 lysine 27 at the DKK1 promoter to restore DKK1 promoter activity Suppression of metastasis and invasion
• Inhibition of Wnt/β-catenin signalling
Uterine / endometrial

MALAT1
Up-regulated with canonical Wnt/β-catenin signalling upon TCF-4 promoter activity as a direct transcriptional target Increases proliferation (Zhao et al., 2014) Contributes to endometrial cancer development via a novel PCDH10-Wnt/β-catenin-MALAT1 regulatory axis Ovarian HOTAIR Activation of Wnt/β-catenin signalling (Mechanism still unknown)
Increases proliferation Increases chemoresistance (Li et al., 2016a,b) Cervical UCA1 Evidence in Wnt/β-catenin signalling is insufficient High UCA1 expression is associated with poorer overall survival in patients. (Zhang et al., 2016a) In female reproductive cancers, lncRNA was shown to modulate expression and activity of essential Wnt modulators in the Wnt/β-catenin signalling pathway and ultimately to change Wnt activity. Moreover, lncRNA can also be affected by Wnt/β-catenin signalling activity. These interactions between lncRNAs and Wnt/β-catenin signalling activity would bring about cellular effects that are associated with several hallmarks of cancers.
2016a). Oncogenic lncRNAs such as lincRNA-p21, HOTAIR and ncRNA-CCND1, with low expression in female reproductive cancer cell lines MCF7 and HeLa, are enriched in secreted exomes, adding to the potential of lncRNAs to aid in cancer diagnosis (Gezer et al., 2014) . Early detection of ovarian cancer would be especially valuable, as this is one of the most lethal female reproductive cancers, in the early stages, it is usually asymptomatic and it lacks good biomarkers for early diagnosis (Cannistra, 2004; Doubeni et al., 2016) .
lncRNAs as direct pharmacological targets lncRNAs may function as suppressing lncRNAs or oncogenic lncRNAs in cells and several methods of directly targeting these lncRNAs have been proposed, although most are still in the early stages of development (Fatima et al., 2015; Huarte, 2015) . Here, we summarize and discuss the current successes and considerations developing lncRNAs as specific therapeutic targets in cancers, including female reproductive cancers (Table 3) . Expression of lncRNAs is often tightly regulated and highly tissue-specific, which make them excellent pharmacological targets for increased specificity, with fewer adverse side effects. The nuclear localization of lncRNAs and their ability to modify epigenetically, in both cis-and trans-acting modes, in addition to their action at transcriptional and post-transcriptional levels, allows for gene locus-specific regulation (Ling et al., 2013; Gloss and Dinger, 2016) . Hence, there are advantages in gene regulating by manipulating lncRNA, despite the larger genome size of lncRNA. Moreover, with more ongoing studies of lncRNA, a recent report has been published on gene targets of lncRNA -'LncRNA2Target' -which contains information of lncRNAto-target genes identified from lncRNA knockdown or overexpression experiments. Approximately 216 differentially expressed gene targets for 68 lncRNAs via qPCR or Western blot analysis were described, while microarray data identified up to 11 389 target genes for 14 lncRNAs (Jiang et al., 2015) .
RNAi therapy. Many oncogenic lncRNAs are overexpressed in cancers, mediating the Wnt-dependent oncogenic pathway, as summarized earlier in this review. The use of RNA interference (RNAi) mechanisms to silence a wide range myriad of genes has been well established in vitro, mostly in cell line systems (Wahlestedt, 2013) . Using welldesigned gene-specific siRNAs and short hairpin RNAs (shRNAs), the expression of genes for target molecules can be effectively reduced, as the target RNAs become degraded following the binding of specific siRNAs/shRNAs (Burnett et al., 2011; Fatima et al., 2015) . Effective targeting of lncRNAs by siRNA/shRNA strategies is also feasible as shown by RNAi strategies in vitro Mohr et al., 2014) . As such, the potential use of RNAi in cancer therapeutics could be exploited to modulate the expression of oncogenic transcripts, including lncRNAs (Mohr et al., 2014) . In cervical cancer , silencing of MALAT1 lncRNA by shRNA reduced both cell migration and invasion . Many of the siRNA-based trials targeting cancers such as hepatocellular carcinoma, pancreatic and renal cell cancers have completed Phase I trial and are moving to Phase II trials (Tabernero et al., 2013) . For instance, the more recent trials targeting DCR-MYC (NCT02314052, NCT02110563), APN401 (NCT03087591, NCT02166255) and siRNA-EphA2-DOPC (NCT01591356) are ongoing as Phase I or II clinical trials or are still in recruitment process (Kanasty et al., 2013; Triozzi et al., 2015) . The development of RNAi therapeutics for use in clinical settings may require the management of a wide range of factors: including possible off-target effects, efficacy and delivery of siRNA and possible immune response and toxicity (Ozcan et al., 2015) . In addition to naked siRNAs, continuous improvement has been made in the delivery of siRNAs with the development of carriers including natural or synthetic lipid carriers such as liposomes, lipidoid particles, solid lipid-based technologies (e.g. stable nucleic acid lipid particle) and polymer carriers (e.g. chitosan and Long non-coding RNAs in Wnt BJP atelocollagen) (Burnett et al., 2011; Dorsett and Tuschl, 2004; Kanasty et al., 2013; Ozcan et al., 2015; Scherman et al., 2017) . The numerous studies and ongoing developmental efforts in RNAi strategies for several cancers, gives confidence in the possibility of implementing RNAi strategies for oncogenic lncRNAs in the clinic for cancers in the future (Burnett et al., 2011; Ozcan et al., 2015) .
Antisense oligonucleotides. Another therapeutic strategy that could be potentially implemented in targeting lncRNAs is the use of antisense oligonucleotides (ASOs). ASOs are short 13-25 oligonucleotides consisting of sequences that are specific and complementary to the target RNA of interest, mediating degradation by RNase H. ASOs may be employed to target oncogenic lncRNAs to inhibit their cellular roles in cancers via Wnt-mediated mechanisms (Bennett and Swayze, 2010; Watts and Corey, 2012) . The use of ASOs in clinical applications has been approved by the FDA for inhibiting cytomegalovirus-associated retinitis, as well as high blood cholesterol, with several other mRNA-targeting ASOs also tested in advanced clinical trials (Haussecker, 2008; Bennett and Swayze, 2010; Watts and Corey, 2012) . This has displayed the great potential of lncRNAs-targeting ASOs in clinical applications for cancer pathogenesis. Particularly, the MALAT1 lncRNA (which is overexpressed in many cancer types and possesses oncogenic functions) was successfully knocked down by the use of ASOs to decrease metastasis in both lung and breast cancer models in mice. In addition, those lncRNAs, which target tumour suppressor genes, are often overexpressed in cancers to decrease the expression of tumour suppressors. ASOs could also be modified to target these antisense transcripts to remove the suppression of the lncRNAs, hence enhance the expression level of tumour suppressors in cancers (Modarresi et al., 2012; Fatemi et al., 2014) . These ASOs are chemically modified structures made up of a mixture of 2 0 -O-methyl RNA and lock nucleic acid (LNA) and are more stable than siRNAs or shRNAs against nuclease cleavage and exhibit enhanced cellular uptake (Veedu and Wengel, 2010) .
Low MW inhibitors. Finally, the use of low MW inhibitors could be another therapeutic strategy for directly targeting lncRNAs. This focuses on blocking the interaction between lncRNAs and their binding partners, or changing the molecular structure of lncRNAs to prevent their interaction with binding partners to drive oncogenesis (Colley and Leedman, 2009; Fatemi et al., 2014; Fatima et al., 2015) . For example, the interaction between HOTAIR, an lncRNA frequently found overexpressed in cancers, with PCR2 or lysine-specific histone demethylase 1 can be blocked with the aid of small molecular inhibitors to reduce breast cancer metastasis (Tsai et al., 2011) . lncRNAs often adopt secondary structures to perform their cellular functions, including during oncogenesis (Ferrè et al., 2016) ; hence, low MW inhibitors could also be used to disrupt secondary structures of lncRNAs, inhibiting their interactions with binding partners during oncogenesis.
Conclusions and future perspectives
In summary, we have highlighted the importance of Wntmediated lncRNA in driving cancer pathogenesis in a variety of female reproductive cancers. Cancers of the female reproductive organs make up more than half of the total of cancers diagnosed and cancer deaths in females annually, making it a clinically relevant disease. In particular, lncRNAs UCA1, NBAT1, CCAT2, HOTAIR and MALAT1 are associated with female reproductive cancers by Wnt/β-catenin pathwaydependent cellular mechanisms, regulating the expression and activity of Wnt/β-catenin modulators.
With the effect of lncRNAs in these cancers and their mechanism of action being gradually elucidated, pharmacological targeting of lncRNAs would be possible to block tumourigenesis (Gupta et al., 2010) . lncRNAs also make good pharmacological targets for cancer treatment because their expression is highly tissue-specific and also noncoding, where they are not translated into any proteins, leading to fewer unwanted adverse side effects (Fatima et al., 2015) .
The stability of lncRNAs in circulating blood and plasma makes them good biomarkers for the management of various female reproductive cancers, including early detection (Wang et al., 2016c) . This is crucial in the case of ovarian cancer, as early diagnosis is often difficult, clinical presentation is usually aggressive, and prognosis is poor.
Finally, the advancement in next-generation sequencing (NGS) technologies has allowed for novel groups of ncRNAs to be discovered. Examples of such novel RNA species include circular RNAs (circRNAs), competing endogenous RNAs and coding and ncRNAs. The discovery of circRNAs, which were observed in great abundance and stability in both tissues and body fluid, has become a potential noninvasive diagnostics approach in diseases such as cancer (Qi et al., 2016a; Wang et al., 2016b) . Moreover, identification of new roles of ncRNAs such as tRNA in cancer has allowed progression in the field of cancer research (Goodarzi et al., 2015; Memczak et al., 2015; Byron et al., 2016; Wang et al., 2016a) . Another class of ncRNA, known as competing endogenous RNAs (ceRNAs), has also been reported. CeRNAs and miRNAs share and compete for same RNA transcripts, thereby regulating gene expression (Denzler et al., 2016) . Finally, a third class of novel ncRNAs, known as the coding and non-coding RNAs, has emerged very recently to have bi-functional roles, possessing both coding and non-coding cellular functions (Kumari and Sampath, 2015; Sampath and Ephrussi, 2016) .
Advancement in NGS technologies and protocols has also facilitated the discoveries of novel RNA-interacting partners, including chromatin-associated proteins, through applications such as RNA-immunoprecipitation, capture hybridization analysis of RNA targets, RNA antisense purification with mass spectrometry, chromatin isolation by RNA purification and enhanced crosslinking-immunoprecipitation (Simon, 2013; McHugh et al., 2015; Yang et al., 2015c; Chu and Chang, 2016; Van Nostrand et al., 2016; Zhang et al., 2016b; Cai et al., 2017) . The discovery of lncRNAs together with complementary NGS technologies would bring about a new paradigm shift in the understanding of the mechanistic, diagnostic and therapeutic roles of lncRNAs in cancers, including Wnt-associated female reproductive cancers. Novel discoveries of novel lncRNA species and lncRNA interacting partners that are associated with the Wnt signalling pathway have not only enriched our understanding on the roles played by these lncRNAs in different cancer cells, including female reproductive cancers, and reinforced the concept of therapeutically targeting the Wnt signalling pathway in cancers but has also greatly increased the potential for lncRNAs as a potential biomarkers or therapeutic targets.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2015/16 (Alexander et al., 2015a,b,c) .
